Leukemia Society Increases Translational Research Grants
NEW YORK-The Leukemia Society of America has increased the funding for its 1998 Translational Research Awards. The awards will now be made for an initial 3 years with an annual maximum of $100,000 in direct costs and 8% overhead, with a possible renewal for an additional 2 years for projects leading to clinical trials.
NEW YORKThe Leukemia Society of America has increased the funding for its 1998 Translational Research Awards. The awards will now be made for an initial 3 years with an annual maximum of $100,000 in direct costs and 8% overhead, with a possible renewal for an additional 2 years for projects leading to clinical trials.
The awards program provides early-stage support for clinical research on leukemia, lymphoma, Hodgkins disease, and myeloma, to develop innovative approaches to treatment, diagnosis, or prevention. The program fosters collaboration between basic and clinical scientists with the intent of enhancing the transfer of basic research findings to clinical usefulness.
In particular, the program is seeking conceptually innovative approaches based on epidemiologic, molecular, cellular, or integrated systems.
Detailed instructions for submission of proposals are contained in the Translational Research Grant Application Packet, which is available from the Societys website: www.leukemia.org.
The packet can also be obtained from the Director of Research Administration, Leukemia Society of America, 600 Third Avenue, New York, NY 10016. Phone: 212-450-8843; fax: 212-856-9686, e-mail: lermandb@leukemia.org. The preliminary deadline is Feb 15, 1998, with completed applications due March 15, 1998.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
